Sequana Medical NV: Press release: Sequana Medical announces 2024 Full Year Results and 2025 Outlook
Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® - US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results